GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Valeo Pharma Inc (TSX:VPH) » Definitions » Long-Term Debt

Valeo Pharma (TSX:VPH) Long-Term Debt : C$33.69 Mil (As of Jan. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Valeo Pharma Long-Term Debt?

Valeo Pharma's Long-Term Debt for the quarter that ended in Jan. 2024 was C$33.69 Mil.

Valeo Pharma's quarterly Long-Term Debt declined from Jul. 2023 (C$61.37 Mil) to Oct. 2023 (C$59.16 Mil) and declined from Oct. 2023 (C$59.16 Mil) to Jan. 2024 (C$33.69 Mil).

Valeo Pharma's annual Long-Term Debt increased from Oct. 2021 (C$1.61 Mil) to Oct. 2022 (C$59.53 Mil) but then declined from Oct. 2022 (C$59.53 Mil) to Oct. 2023 (C$59.16 Mil).

Valeo Pharma Long-Term Debt Historical Data

The historical data trend for Valeo Pharma's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valeo Pharma Long-Term Debt Chart

Valeo Pharma Annual Data
Trend Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Long-Term Debt
Get a 7-Day Free Trial 1.00 2.97 1.61 59.53 59.16

Valeo Pharma Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 59.70 61.42 61.37 59.16 33.69

Valeo Pharma  (TSX:VPH) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Valeo Pharma Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Valeo Pharma's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Valeo Pharma (TSX:VPH) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Valeo Pharma Inc (TSX:VPH) » Definitions » Long-Term Debt
Comparable Companies
XCNQ:CANN TSX:XLY XCNQ:XTRX TSXV:MPH XCNQ:BAMM TSX:CTX NEOE:TILT XCNQ:MVMD XCNQ:VIN XCNQ:PWR ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
VPHIF:USA
Address
16667, Hymus Boulevard, Kirkland, QC, CAN, H9H 4R9
Website
https://www.valeopharma.com
Valeo Pharma Inc is a Canadian specialty pharmaceutical company focused on acquiring either through acquisitions, in-licensing, or similar arrangements. The company operates in two divisions: Branded prescription products and Niche hospital injectable products. Its product portfolio includes medicines for Respiratory/Allergy, Ophthalmology, Neurology, and Oncology.
Executives
Luc Mainville Senior Officer

Valeo Pharma (TSX:VPH) Headlines

No Headlines